Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Non Operating Income (2016 - 2026)

Catalyst Pharmaceuticals filings provide 13 years of Non Operating Income readings, the most recent being $11.0 million for Q1 2026.

  • On a quarterly basis, Non Operating Income rose 38.87% to $11.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $28.8 million, a 6.35% increase, with the full-year FY2025 number at $25.7 million, up 21.75% from a year prior.
  • Non Operating Income hit $11.0 million in Q1 2026 for Catalyst Pharmaceuticals, up from $10.1 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $11.3 million in Q4 2024 to a low of -$833000.0 in Q3 2023.
  • Median Non Operating Income over the past 5 years was $2.2 million (2022), compared with a mean of $4.0 million.
  • The widest YoY moves for Non Operating Income: up 3008.45% in 2022, down 622.58% in 2022.
  • Catalyst Pharmaceuticals' Non Operating Income stood at $2.2 million in 2022, then soared by 127.23% to $5.0 million in 2023, then soared by 126.08% to $11.3 million in 2024, then fell by 11.32% to $10.1 million in 2025, then grew by 9.37% to $11.0 million in 2026.
  • The last three reported values for Non Operating Income were $11.0 million (Q1 2026), $10.1 million (Q4 2025), and $4.8 million (Q3 2025) per Business Quant data.